CLX

Business Profile & Competitive Position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products best known for brands such as Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional segment sells under Purell, CloroxPro, and Clorox Healthcare. For fiscal 2026, Clorox reported net sales of $6.7 billion.

Reading the current financials alongside that scale gives a mixed view of competitive strength. The company’s net margin is 8.7%, which means it still converts sales into profit, but its return on equity is -1893.5%. A negative ROE of that magnitude usually signals a deeply depleted, or even negative, equity base rather than a precipitous operating loss; the net margin is still positive. That combination suggests that brand recognition remains intact, but balance-sheet erosion is preventing the business from generating positive returns on book equity. In other words, sales and margins are not currently translating into shareholder-value creation in a conventional ROE sense.

Another constraint on pricing power is customer concentration. Clorox disclosed that Walmart alone accounted for 26% of consolidated fiscal 2026 net sales, and its five largest customers represented about half of net sales. That kind of concentration gives major retailers significant bargaining leverage on price, promotion, and shelf placement, which can compress margins even for household-name brands.

Financial Posture

As of the current snapshot, Clorox carries a market capitalization of $10.6 billion and trades at a price-to-earnings ratio of 18.2. Its net margin stands at 8.7%, its ROE at -1893.5%, and its beta at 0.54. The stock price is $87.76, with a 50-day exponential moving average of $98.51 and an RSI of 23.0.

The beta of 0.54 is consistent with a defensive consumer-staples name: the stock historically has moved roughly half as much as the overall market. At the same time, a P/E of 18.2 is not especially demanding relative to many staples peers, though that valuation partly reflects the earnings reset the company has experienced. The most striking metric is the -1893.5% ROE. Because ROE is net income divided by shareholders’ equity, such an extreme negative figure generally arises when the equity denominator is very small or negative, often driven by cumulative net losses, heavy buybacks, or asset write-downs. That makes the balance sheet, not just the income statement, the first place to inspect when evaluating whether Clorox’s current margin can support durable value creation.

Strategic Priorities & Outlook

Clorox’s most recent 10-K frames the company as a multinational producer with about 9,200 employees operating in roughly 25 countries and selling in about 95 markets. In April 2026, it completed the acquisition of GOJO Industries, adding the Purell brand and expanding its health and hygiene footprint as well as its business-to-business presence.

The company’s stated strategy is built around its IGNITE framework, which is focused on four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Operationally, Clorox is working to complete and optimize a new enterprise resource planning (ERP) system and a broader digital transformation. The stated goal is to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building, while investing in strong brands, strategic digital capabilities, and a streamlined operating model.

Near-term priorities also include advancing health and hygiene expansion and portfolio optimization, notably by integrating GOJO and growing in professional and institutional channels. However, fiscal 2026 was described as a year of decline in organic sales and earnings, with diluted EPS down 26%. The filing attributed part of the weakness to macroeconomic headwinds and ERP transition timing that had pulled some sales into fiscal 2025. Separately, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, after which Clorox purchased P&G’s 20% interest, while Glad retained core intellectual property licenses on a royalty-free basis. Each of these items—GOJO integration, ERP rollout, customer concentration, and the Glad venture restructuring—will likely shape results over the next several quarters.

Macro & Geopolitical Exposure

As a Household & Personal Products company, Clorox is exposed to a familiar set of macro factors. Raw-material costs are a persistent consideration: resins and plastics for Glad bags, chemicals and packaging for cleaning products, and agricultural or food-related inputs for Hidden Valley and other food brands. Freight and logistics costs also affect margins, especially given the volume and weight of many household products.

Currency translation is another factor, since Clorox sells in about 95 markets even though it operates in roughly 25 countries. A stronger U.S. dollar can reduce the dollar value of overseas revenue, while tariffs or trade-policy shifts can affect imported packaging and raw materials.

Demand characteristics are mostly defensive, but not immune to pressure. Inflation-weary consumers may trade down to private-label cleaners, delay discretionary purchases such as water filters or charcoal, or buy only on promotion. Regulatory exposure is also inherent to the industry, spanning EPA, FDA, FTC, and state-level rules around product safety, labeling, disinfectant claims, and sustainability disclosures. The high customer concentration with mass retailers further ties the company to promotional calendars and inventory cycles at a small number of buyers.

Recent Developments

The most recent headline, dated September 14, 2026, from defenseworld.net, reported that NewEdge Advisors LLC acquired shares of The Clorox Company. The filing itself does not indicate a strategic shift, but institutional accumulation is often watched by traders as a positioning signal.

On September 9, 2026, Seeking Alpha published the transcript of Clorox’s presentation at the Barclays 19th Annual Global Consumer Staples Conference. These events can move the stock when management updates annual guidance, margin expectations, or integration milestones for the GOJO acquisition.

Also on September 9, 2026, 247wallst.com included Clorox among five well-known high-yield stocks that passive-income investors are buying near 52-week lows. That fits with the current snapshot showing the stock well below its 50-day EMA of $98.51 and an RSI of 23.0, a reading typically associated with short-term oversold conditions.

On September 3, 2026, Zacks asked whether cost savings can offset inflation and protect Clorox’s margins. That question is essentially the central debate for the stock right now: whether ERP efficiencies, pricing actions, and GOJO synergies can stabilize an 8.7% net margin against input and retailer pressure.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Clorox has beaten earnings estimates six times, giving it a 75% beat rate with an average earnings surprise of 9.6%. The average five-day price move in the trading sessions after earnings has been 1.67%, which is classified as an upward drift.

The recent quarter-to-quarter path, however, shows that headline beats have not always produced immediate gains. In the most recent quarter, reported August 3, 2026, Clorox earned $1.66 versus an estimate of $1.64, a 1.2% beat; the stock rose 6.52% the next day and 9.61% over the following five days. By contrast, the April 30, 2026 report delivered a 5.8% beat—$1.64 versus $1.55—but the stock fell 9.67% the next day and 4.49% over the next five sessions.

The February 3, 2026 quarter was a miss: EPS of $1.39 versus an estimate of $1.43, a -2.8% surprise. Despite the miss, the stock rose 2.43% the next day and 5.63% over the subsequent five trading days. The November 3, 2025 quarter delivered a 3.9% beat, with $0.85 versus $0.818, but the five-day drift was -4.08% even though the next-day move was +1.17%.

What this pattern suggests is that the market’s real expectation around Clorox’s reports can differ from the stated consensus, and that guidance, margin commentary, and GOJO integration updates often matter more than the headline EPS beat. The next scheduled report is November 3, 2026, after the market close, with a consensus EPS estimate of $1.11.

For a deeper dive into how analysts are weighing Clorox’s margin recovery, GOJO integration risk, and valuation relative to the broader consumer-staples complex, consult the platform’s full institutional verdict before forming any trading or investment view.